Bone health and DXA monitoring¶
Bone health is the long-term medical issue where transfeminine populations face the most concrete, measurable risk if HRT is interrupted, dosed inadequately, or replaced by androgen blockade alone. The data converge on a reassuring pattern when estradiol is maintained — bone mineral density (BMD) is preserved or modestly increased — and a sharp warning when it is not: post-orchiectomy patients without adequate estrogen replacement lose bone at rates comparable to prostate-cancer surgical castration, roughly 2–3% per year at the spine and hip in the first year.
This page synthesizes Wiepjes 2017/2019/2020, Schagen 2020, Endocrine Society Hembree 2017, and the ISCD 2019 transgender position statement for adults on long-term HRT, especially those who have undergone Orchiectomy and therefore depend on exogenous estradiol for skeletal maintenance.
Why BMD matters in transfeminine adults¶
Three independent lines of evidence make this a priority topic, not a peripheral one.
Lower baseline BMD. Pre-treatment cohorts (Van Caenegem; COMET; Amsterdam) consistently find trans women have lower areal BMD at lumbar spine, femoral neck, and total hip than age-matched cis men despite comparable testosterone — attributable to lower lean mass, lower physical activity, and lower 25(OH)D rather than sex-steroid status. Roughly 16–25% meet criteria for low BMD (Z-score ≤ −2.0) before any hormones are started.
Elevated fracture incidence. Wiepjes 2020 (Dutch nationwide cohort) found trans women aged 50+ had elevated fracture risk versus age-matched cis men, and 41.8% of fractures occurred at hip, spine, forearm, or humerus — the classic osteoporotic distribution — versus 26.6% in age-matched reference men.
Modifiable compounding risk. Lower 25(OH)D, lower weight-bearing activity in some subgroups, and — most importantly — structural reliance on exogenous estradiol after orchiectomy. The prostate-cancer ADT literature established that estrogen deficiency, not testosterone deficiency, drives male skeletal loss. Post-orchi patients have no endogenous estradiol production of consequence, so BMD trajectory is set by adherence and serum E2 rather than by the gonadectomy itself.
What HRT does to BMD¶
Wiepjes 2017 (ENIGI multicenter, 231 trans women, one year on HRT) found BMD increases at all three measured sites: lumbar spine +3.67%, total hip +0.97%, femoral neck +1.86%. Vlot 2019 (same cohort) confirmed bone-resorption markers (CTX, P1NP) decreased on feminizing HRT.
Wiepjes 2019 extended the Amsterdam cohort to ten years (711 trans women). BMD did not decline at any site over a decade, and at the lumbar spine showed sustained increase. Higher serum estradiol tertiles were associated with larger BMD gains, supporting a dose-response relationship within therapeutic range.
Caveat: the Amsterdam cohort overwhelmingly used cyproterone plus oral or transdermal estradiol with serum E2 typically 100–200 pg/mL. Generalization to spironolactone-based regimens is reasonable but not directly tested at the same scale. Generalization to GnRH-agonist monotherapy without estrogen is not warranted — see the warning below.
Schagen 2020 adolescent data¶
Schagen et al. (51 transgirls, 36 receiving GnRHa plus subsequent estradiol) tracked bone mass through pubertal suppression. Findings adults should understand because they shape lifetime fracture risk:
- Baseline BMD Z-scores were well below the cis-male population mean — replicating the adult pre-treatment finding in pediatrics.
- During GnRHa monotherapy, areal BMD and BMAD stabilized or decreased slightly while Z-scores fell because peers continued accruing bone through puberty.
- After estradiol was added, BMAD increased and absolute accrual resumed, but Z-scores remained below zero at end of follow-up.
The implication is that puberty-suppressed transfeminine adolescents enter adulthood with lower peak bone mass than cis-female peers and a meaningfully lower peak than they would have achieved through endogenous male puberty. This is the strongest argument for adequate, uninterrupted estradiol from the moment GnRHa is started, and for vigilance about lifelong adherence.
DXA cadence¶
The Endocrine Society Hembree 2017 guideline recommends BMD measurement when osteoporosis risk factors exist, specifically in those who stop sex hormone therapy after gonadectomy. Most specialty clinics now obtain a baseline anyway given the high prevalence of pre-treatment low BMD.
| Scenario | DXA cadence |
|---|---|
| Pre-HRT or pre-orchi with risk factor1 | Baseline scan |
| Adherent post-orchi, adequate E2, no factors | Every 2–3 years |
| Treatment-response monitoring (ISCD) | Every 1–2 years until BMD stabilizes |
| HRT gap > 3–6 months | Earlier next scan; review reasons |
| Persistent E2 < 50 pg/mL | Annual |
| Low-trauma fracture, weight loss > 10% | Prompt scan |
| Glucocorticoid initiation, AI exposure | Prompt scan |
| Universal screening | Age 65 (50 if any risk factor) |
| Agonadal and off HRT | Follow agonadal/postmenopausal cis guidelines |
The "5 years off HRT after gonadectomy" threshold cited in older guidance is a ceiling, not a target. Any post-orchi patient who has been off estrogen for more than a few months warrants an earlier scan and a frank conversation about resumption.
T-score and Z-score interpretation¶
Transfeminine DXA reading is implemented inconsistently — one audit found 67% of T- and Z-scores in transgender patients were calculated against the wrong reference. The 2019 ISCD official positions for transfeminine adults:
| Score | Reference database | Notes |
|---|---|---|
| Z-score (trans women) | Cis-female normative database (matches identity) | Quality: good |
| T-score (all trans) | Uniform non-race-adjusted Caucasian female | Quality: fair |
| Non-binary | Database matching sex recorded at birth | No validated alternative |
| Osteoporosis Dx age 50+ | T-score ≤ −2.5 against female reference | Same as cis women |
| Pre-50 / pre-menopausal | Z-score ≤ −2.0 ("below expected range for age") | Convention extends to trans women < 50 |
The cis-female database is more conservative for AMAB bodies, producing lower Z-scores than a cis-male comparison would. The practical consequence is that a trans woman whose absolute BMD is identical to a cis man's will read as "low for a woman" against the female reference. Some clinicians order both readings to disambiguate; ISCD permits a male-reference Z-score to be calculated alongside on request.
Calcium, vitamin D, and activity¶
The modifiable substrate on which estrogen acts.
| Nutrient / target | Adults < 50 | Adults ≥ 50 |
|---|---|---|
| Calcium total (diet + supp) | 1,000 mg/day | 1,200 mg/day |
| Vitamin D baseline | 800–1,000 IU/day | 800–1,000 IU/day |
| Serum 25(OH)D target | > 30 ng/mL (75 nmol/L) | > 30 ng/mL |
| Repletion (deficient) | 50,000 IU weekly × 8 wk, then 1,000–2,000 IU/day | same |
Prefer dietary calcium (dairy, fortified plant milks, leafy greens, sardines) over supplements; some meta-analyses signal modest cardiovascular risk with high-dose supplemental calcium. Check 25(OH)D in any patient with BMI > 27, malabsorption, limited sun exposure, or low dietary intake. Correcting vitamin D deficiency before interpreting a low DXA is essential — osteomalacia mimics osteoporosis on imaging but reverses with repletion alone.
Weight-bearing activity (walking, resistance training, jogging) is the third pillar. Karolinska transgender muscle data (Wiik/Lundberg) show thigh muscle volume drops 5–7% on HRT but strength is preserved with continued training; resistance training independently builds bone at lumbar spine and femoral neck.
Treatment thresholds and pharmacotherapy¶
When BMD falls into osteoporotic range or fracture occurs, the same drug classes used in cis populations apply. There are no transgender-specific RCTs, but post-orchi pathophysiology is closely analogous to surgical menopause and ADT-induced bone loss.
| Indication for pharmacotherapy |
|---|
| T-score ≤ −2.5 at spine, hip, or femoral neck (female ref), age ≥ 50 |
| Prior hip or vertebral fragility fracture, any age |
| T-score −1.0 to −2.5 plus FRAX MOF ≥ 20% or hip ≥ 3% |
| Z-score ≤ −2.0 plus fragility fracture, age < 50 |
| Glucocorticoid ≥ 7.5 mg prednisone-equivalent for ≥ 3 months |
FRAX is not validated in transgender populations and uses sex-specific data; most clinicians enter affirmed gender consistent with ISCD's reference choice, but interpret as approximate.
| Agent | Dose | Use case |
|---|---|---|
| Alendronate | 70 mg PO weekly | Standard first-line |
| Risedronate | 35 mg PO weekly | First-line alternative |
| Zoledronic acid | 5 mg IV annually | Adherence or GI issues; equivalent fracture reduction |
| Denosumab | 60 mg SC every 6 months | RANKL inhibitor; useful in CKD |
| Romosozumab | 210 mg SC monthly × 12 months | Very high fracture risk; CV boxed warning |
| Teriparatide / abaloparatide | Daily SC × 24 months | Severe osteoporosis or multiple fractures |
Denosumab discontinuation rebound
Stopping denosumab causes rapid rebound bone loss and a spike in vertebral fracture risk within 6–12 months of the last dose, regardless of how long therapy continued. Bridging to a bisphosphonate is mandatory. For transfeminine patients, adherence interruptions can cascade — do not start denosumab without a clear continuation or transition plan.
In all cases for transfeminine patients, the first treatment question is whether HRT is adequate. Optimizing serum estradiol into the 100–200 pg/mL range and confirming testosterone suppression often produces meaningful BMD gains over 1–2 years and may obviate or delay the need for a bisphosphonate, especially when low BMD is driven by inadequate estrogen rather than intrinsic bone disease. See HRT Continuity for adherence framing.
HRT interruption: the highest-priority risk¶
Post-orchi HRT interruption is biologically equivalent to surgical castration
Without estradiol, post-orchi patients are in the same hormonal state as men on GnRH-agonist ADT for prostate cancer: 2–3% BMD loss per year at hip and spine in the first year, with continued slower loss thereafter. The loss is driven by estrogen deficiency, not testosterone deficiency. Direct prospective transfeminine data are sparse because sustained gaps are uncommon in research cohorts, but the ADT analogue is tight.
Practical thresholds:
| Gap length | Action |
|---|---|
| Weeks (insurance lapse, supply) | Resume HRT; no special action; not measurable on BMD |
| 3–6 months | Earlier DXA at next clinical encounter; review why the gap occurred |
| 1+ years post-orchi | Prompt DXA; vitamin D and calcium assessment; fracture-risk evaluation; low threshold for pharmacotherapy |
| Permanent post-orchi cessation | Treat as agonadal/surgically-menopausal for screening and treatment |
Resumption of estradiol alone may not fully restore lost bone within a clinically useful timeframe in older patients, which is why prevention (adherence) matters more than recovery.
GnRH-agonist monotherapy without estrogen¶
GnRH agonist without estradiol is the closest direct analogue to ADT
GnRH Agonists used as anti-androgen monotherapy without concurrent estradiol produce a hypogonadal state with both testosterone and estradiol at near-castrate levels. The prostate-cancer ADT literature documents 2–3% per year BMD loss on this regimen. Gava 2020 (5-year leuprolide vs CPA in trans women) found preserved BMD in both arms only because both groups received adequate estradiol, not because GnRHa is bone-neutral.
Adolescents on GnRHa monotherapy as part of pubertal suppression are the only transfeminine population for whom unopposed GnRHa is conventionally accepted — and even there, duration is finite, Z-scores fall during the gap, and addition of estradiol is the default plan. Adult GnRHa regimens require concurrent estradiol for skeletal safety.
Sources¶
- Wiepjes CM, Vlot MC, Klaver M, et al. Bone Mineral Density Increases in Trans Persons After 1 Year of Hormonal Treatment. J Bone Miner Res. 2017;32(6):1252-1260. https://onlinelibrary.wiley.com/doi/10.1002/jbmr.3102
- Wiepjes CM, de Jongh RT, de Blok CJM, et al. Bone Safety During the First Ten Years of Gender-Affirming Hormonal Treatment in Transwomen and Transmen. J Bone Miner Res. 2019;34(3):447-454. https://onlinelibrary.wiley.com/doi/abs/10.1002/jbmr.3612
- Wiepjes CM, den Heijer M, Bremmer MA, et al. Fracture Risk in Trans Women and Trans Men Using Long-Term Gender-Affirming Hormonal Treatment: A Nationwide Cohort Study. J Bone Miner Res. 2020;35(1):64-70. https://pmc.ncbi.nlm.nih.gov/articles/PMC7003754/
- Schagen SEE, Wouters FM, Cohen-Kettenis PT, et al. Bone Development in Transgender Adolescents Treated With GnRH Analogues and Subsequent Gender-Affirming Hormones. J Clin Endocrinol Metab. 2020;105(12):e4252-e4263. https://academic.oup.com/jcem/article/105/12/e4252/5903559
- Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017;102(11):3869-3903. https://academic.oup.com/jcem/article/102/11/3869/4157558
- Rosen HN, Hamnvik OR, Jaisamrarn U, et al. Bone Densitometry in Transgender and Gender Non-Conforming (TGNC) Individuals: 2019 ISCD Official Position. J Clin Densitom. 2019;22(4):544-553. https://pubmed.ncbi.nlm.nih.gov/31327665/
- Vlot MC, Wiepjes CM, de Jongh RT, et al. Gender-Affirming Hormone Treatment Decreases Bone Turnover in Transwomen and Older Transmen. J Bone Miner Res. 2019;34(10):1862-1872. https://onlinelibrary.wiley.com/doi/full/10.1002/jbmr.3762
- UCSF Gender Affirming Health Program. Bone health and osteoporosis. https://transcare.ucsf.edu/guidelines/bone-health-and-osteoporosis
- Fitzpatrick LA. Treatment-Related Osteoporosis in Men with Prostate Cancer. Clin Cancer Res. 2006;12(20 Pt 2):6315s-6319s. https://aacrjournals.org/clincancerres/article/12/20/6315s/191420/
-
Prior fragility fracture, prolonged amenorrhea-equivalent, glucocorticoid use, eating-disorder history, BMI < 20, family history of osteoporosis, or planned orchiectomy in the near term. ↩